RESUMO
Case series summary: The present report describes middle ear cholesteatoma in two cats and also the use of video-otoscopy and flushing to assist with the diagnosis. CT and video-otoscopic examination and flushing were performed in two cats, a 13-year-old mixed breed spayed female cat and a 1-year-old mixed breed male cat, with middle ear cholesteatomas. During the procedure, keratinous material from the middle ears was collected for histopathological evaluation, demonstrating findings consistent with cholesteatoma, and the middle ears were flushed extensively. Relevance and novel information: There is little information about middle ear cholesteatoma in cats, and to the authors' knowledge, there are no reports in cats investigating the use of video-otoscopy to aid in the diagnosis of aural cholesteatoma, and this report demonstrates that it can aid in the diagnosis of this condition in cats. In addition, one of the cats had a concurrent otic polyp, which has not been previously reported in cats with cholesteatoma. Additionally, this is the first report of cholesteatoma in a young cat. The access to the cholesteatoma material was via ventral bulla osteotomy in one cat and via external canal without video-otoscopy in the other. More information regarding cholesteatoma in cats will help identify potential similarities and differences of this condition in cats compared with humans and dogs.
RESUMO
Os anticorpos monoclonais são tema de pesquisa na medicina humana. Eles têm como alvo receptores específicos ou determinadas citocinas e são altamente específicos e eficazes no bloqueio de sua molécula-alvo. O lokivetmab é um anticorpo monoclonal caninizado anti-IL-31 que se liga especificamente à IL-31 circulante, e foi recentemente aprovado para o tratamento da dermatite atópica canina. Atualmente, o lokivetmab é o primeiro anticorpo monoclonal terapêutico utilizado na medicina veterinária. Este trabalho teve como objetivo revisar e atualizar os clínicos sobre esse novo anticorpo monoclonal que está disponível para tratamento da dermatite atópica canina.
Monoclonal antibodies have been studied in human medicine for a while. They target specific receptors and cytokines, and are highly specific and effective in blocking their target molecule. Lokivetmab is a monoclonal caninised anti-IL-31 antibody that was recently approved for the treatment of atopic dermatitis in dogs. Currently, no other therapeutic monoclonal antibody is used in veterinary medicine. The goal of this review of literature is to update clinicians on this new biological option for the treatment of canine atopic dermatitis.
Los anticuerpos monoclonales son tema de investigación en la medicina humana, y tienen como blancos receptores específicos o determinadas citoquinas. Son muy específicos y eficientes en el bloqueo de su molécula blanco. El lokivetmab es un anticuerpo monoclonal caninizado anti-IL-31 que se une específicamente a la IL-31 circulante, que fue aprobado recientemente para el tratamiento de la dermatitis atópica canina. Actualmente este fármaco representa el primer anticuerpo monoclonal terapéutico que se utiliza en medicina veterinaria. Este trabajo tiene como objetivo revisar y actualizar las informaciones científicas sobre este nuevo anticuerpo monoclonal que se encuentra disponible para el tratamiento de la dermatitis atópica en perros.
Assuntos
Animais , Cães , Anticorpos Monoclonais/administração & dosagem , Anticorpos Monoclonais/uso terapêutico , Dermatite Atópica/terapia , Dermatite Atópica/veterinária , Interleucinas/antagonistas & inibidoresRESUMO
Os anticorpos monoclonais são tema de pesquisa na medicina humana. Eles têm como alvo receptores específicos ou determinadas citocinas e são altamente específicos e eficazes no bloqueio de sua molécula-alvo. O lokivetmab é um anticorpo monoclonal caninizado anti-IL-31 que se liga especificamente à IL-31 circulante, e foi recentemente aprovado para o tratamento da dermatite atópica canina. Atualmente, o lokivetmab é o primeiro anticorpo monoclonal terapêutico utilizado na medicina veterinária. Este trabalho teve como objetivo revisar e atualizar os clínicos sobre esse novo anticorpo monoclonal que está disponível para tratamento da dermatite atópica canina.(AU)
Monoclonal antibodies have been studied in human medicine for a while. They target specific receptors and cytokines, and are highly specific and effective in blocking their target molecule. Lokivetmab is a monoclonal caninised anti-IL-31 antibody that was recently approved for the treatment of atopic dermatitis in dogs. Currently, no other therapeutic monoclonal antibody is used in veterinary medicine. The goal of this review of literature is to update clinicians on this new biological option for the treatment of canine atopic dermatitis.(AU)
Los anticuerpos monoclonales son tema de investigación en la medicina humana, y tienen como blancos receptores específicos o determinadas citoquinas. Son muy específicos y eficientes en el bloqueo de su molécula blanco. El lokivetmab es un anticuerpo monoclonal caninizado anti-IL-31 que se une específicamente a la IL-31 circulante, que fue aprobado recientemente para el tratamiento de la dermatitis atópica canina. Actualmente este fármaco representa el primer anticuerpo monoclonal terapéutico que se utiliza en medicina veterinaria. Este trabajo tiene como objetivo revisar y actualizar las informaciones científicas sobre este nuevo anticuerpo monoclonal que se encuentra disponible para el tratamiento de la dermatitis atópica en perros.(AU)
Assuntos
Animais , Cães , Dermatite Atópica/terapia , Dermatite Atópica/veterinária , Anticorpos Monoclonais/uso terapêutico , Anticorpos Monoclonais/administração & dosagem , Interleucinas/antagonistas & inibidoresRESUMO
CASE SUMMARY: It is described a case of a 10-month-old female mixed-breed cat with left ear discharge of approximately 6 days' duration prior to the admission. Secretions were collected from both ears using a sterile swab for cytological and mycological analysis. A pyogranulomatous inflammatory infiltrate (predominantly characterized by the presence of neutrophils and macrophages) with the presence of cocci, rods and many yeast-like structures were seen on cytological analysis; the fungal culture confirmed the presence of the Sporothrix schenckii complex. Upon diagnosis of fungal otitis due to the S schenckii complex, treatment with oral itraconazole was administered. After 4 weeks of treatment, no S schenckii complex colonies were isolated, and clinical recovery had occurred. RELEVANCE AND NOVEL INFORMATION: Although rare, clinicians must be aware of atypical presentations of sporotrichosis, as in this case of external otitis. This is of clinical relevance because this infection has been reported in several countries and is defined as a zoonotic disease.